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Abstract
Hepatitis C virus (HCV) is a major cause of liver 
diseases including liver cirrhosis and hepatocellular 
carcinoma. Approximately 3% of the world population 
is infected with HCV. Thus, HCV infection is considered 
a public healthy challenge. It is worth mentioning, that 
the HCV prevalence is dependent on the countries 
with infection rates around 20% in high endemic 
countries. The review summarizes recent data on HCV 
molecular biology, the physiopathology of infection 
(immune-mediated liver damage, liver fibrosis and 
lipid metabolism), virus diagnostic and treatment. In 
addition, currently available in vitro , ex vivo  and animal 
models to study the virus life cycle, virus pathogenesis 
and therapy are described. Understanding of both host 
and viral factors may in the future lead to creation of 
new approaches in generation of an efficient therapeutic 
vaccine.
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Core tip: Brief overviews on epidemiology of hepatitis C 
virus (HCV), virus morphology and the virus life cycle are 
presented. A special attention was focused on in vitro 
and in vivo models that are currently used to study the 
HCV infection. In fact, extensive use of existing models 
and creating a new ones is a way to reveal important 
events in the virus-cell interaction. In particular, the 
models might shed light on the mechanisms behind 
virus induced pathogenesis and chronicity, and by 
that contribute to the development of new drugs and 
prophylactic vaccine. Recently, multiple therapies with 
a pan-genotypic activity appeared on the market. The 
new agents (third generation) and new inhibitors (entry 
inhibitors, release inhibitors) being studied, should allow 
to cure most of the patients in the mid-term, if they will 
have equal access to the therapy.
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INTRODUCTION
The hepatitis C virus (HCV) is a major blood borne 
human pathogen. There are approximately 120-130 
million or 3% of the total world population that are 
HCV infected (Figure 1). According to World Health 
Organization (WHO), annually there are about 3-4 
million new cases of infection[1,2]. HCV is considered a 
major public health issue, since the virus is the etiological 
factor of chronic hepatitis that frequently progress to 
a cirrhosis and hepatocellular carcinoma (HCC). In 
developed countries, the most important route of HCV 
transmission is intravenous drug abuse, whereas in 
resource-poor countries invasive procedures or injection-
based therapies with contaminated instruments are the 
predominant source of new infections[3].
Without treatment, most of the acute infections 
progress to chronic ones, followed by liver disease, 
such as cirrhosis and HCC. Alcohol abuse and the 
metabolic syndrome are the main cofactors influencing 
the progression to advanced liver disease and HCC[4]. 
Each year, about a third of liver transplantations are 
performed on patients with complications associated 
with the HCV infection, with decompensated cirrhosis or 
HCC[5]. In the next decade, an increase in the burden of 
hepatitis C is expected because of aging of the currently 
infected population[6,7]. During that period, the number 
of HCV-related cirrhosis cases is estimated to increase 
by 31% and HCC by approximately 50%[6] with an 
additive effect due to the occurrence of the metabolic 
syndrome[8,9]. Thus, HCV infection represents a major 
public health issue that should be addressed with strong 
policy interventions to effectively identify and treat HCV 
infected patients.
There are seven genotypes (gt 1-7) and numerous 
subtypes of HCV. The rate of infection and subtype 
prevalence are country depend. The difference between 
the infection rate in low and high endemic countries is 
about 20% (Figure 1)[10,11]. For example, North America, 
Western Europe and North and Australia’s have the 
lowest HCV prevalence. Conversely, in Asian and African 
countries the virus prevalence is high. The highest virus 
prevalence was registered in Egypt, where 22% of 
population is infected[12]. It has been postulated that the 
epidemic has been caused by extensive iatrogenic tran-
smission during the era of parenteral-antischistosomal-
therapy mass-treatment campaigns before 1985[13].
MOLECULAR BIOLOGY OF HCV
HCV morphology and parameters
HCV is a small, enveloped, positive single-stranded 
RNA virus that belongs to the Flaviviridae family, genus 
Hepacivirus. Analysis of viruses from plasma and 
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from cell culture supernatant indicated that enveloped 
particles are icosahedral and 56-65 nm[14,15] in diameter, 
while and the viral core is about 45 nm[14,15]. Viral spikes 
on the membrane of the virion are about 6 nm[14] and 
they are formed by heterodimers of E1 and E2 glyco-
proteins. In fact, the population of the extracellular HCV 
particles is heterogeneous. Particles are pleomorphic 
and size, buoyant density, and infectivity might differ 
significantly[14,15]. A large majority of particles is non-
infectious. Interestingly, the buoyant densities of infec-
tious particles isolated from serum and from cell culture 
medium are different. A significant amount of the 
particles are associated with cellular lipoproteins making 
that a hallmark mark of HCV[16,17]. The pattern of virus-
associated lipoproteins might differ and several of those 
are associated with HCV most frequently: low density 
lipoproteins (LDL), very low-density lipoproteins (VLDL) 
and apolipoproteins (Apo) A1, B, C and E (Figure 2)[18]. 
The viral particles associated with lipoproteins are called 
“lipoviral particles (LVP)”. More details on LVP are given 
in “Virus assembly and release” section. Detailed update 
on HCV-associated lipoproteins is given in the review by 
Grassi et al[19]. 
Viral genome 
The genome of HCV is approximately 9600 nucleotides 
long (Figure 3A). It contains two highly conserved 
untranslated regions (UTR) 5’-UTR and 3’-UTR that are 
flanking a single open reading frame (ORF). Dependent 
on the genotype, the ORF might contain from 9030 to 
9099 nucleotides and it is coding for a single polyprotein 
precursor of 3010 to 3033 amino acids (aa), respectively 
(Figure 3B and C)[20,21]. Translation occurs in the 
endoplasmic reticulum and it is initiated by IRES at the 5’ 
UTR[22].
5’-untranslated region
The 5’-UTR is highly conserved including special site 
to control the HCV genome replication and the viral 
polyprotein translation. The region is 341 nucleotides 
long and it contains four distinct domains (Ⅰ-Ⅳ). The 
first 125 nucleotides of 5’UTR spanning the domains 
Ⅰ and Ⅱ have been shown to be essential for the 
viral RNA replication. The domains Ⅲ-Ⅳ composes an 
internal ribosomal entry site (IRES) involved in ribosome 
binding which can initiate viral polyprotein translation 
in a cap-independent manner[20]. The initiation of HCV 
protein synthesis requires the ordered assembly of 
ribosomal pre-initiation complexes, beginning with 
the association of the small (40S) ribosomal subunit 
with a messenger RNA (mRNA). The cap-independent 
translation begins with the 40S ribosome binding and 
the scanning to the initiation codon which is followed by 
association with the 60S ribosomal subunit to form an 
active 80S ribosome[21,22]. The HCV IRES is folded into 
highly structured domains which are called Ⅱ to Ⅳ. 
The mutational analysis of the IRES domains suggested 
that a structural integrity was necessary for an efficient 
protein synthesis both in vitro and in vivo[23-25].
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3’-untranslated region
The 400 nucleotides long 3’-UTR region is thought to 
playing a crucial role in the HCV replication. The region is 
highly conserved and it is divided into three functionally 
parts: A variable sequence of 40 nucleotides, a variable 
internal poly (U/UC) rich tract of 30 to 80 nucleotides 
(depending on the HCV strains), which is followed by a 
highly conserved 98-nucleotide X-tail containing three 
stable stem loop (SL) structures called: 3’SL1, 3’SL2, 
3’SL3[25].
Viral proteins
The translation occurs in the endoplasmic reticulum 
and it is initiated by IRES at the 5’UTR[25]. A single 
polyprotein precursor is processed by cellular and viral 
proteases into ten proteins (Figure 3B). Three structural 
proteins (core, E1, E2) are located at the amino-terminal 
part of the polyprotein and are essential components of 
the virions. Seven nonstructural proteins (p7, NS2, NS3, 
NS4A, NS4B, NS5A, NS5B) are located in the remaining 
part of the polyprotein and these proteins are involved in 
particle morphogenesis, RNA replication and in regulation 
of cell functions (Table 1). It is worth mentioning, that 
the structural and non-structural proteins of HCV are 
multifunctional. A brief characterization of the protein is 
given below.
Core protein (p22)
The core protein of HCV is translated as an immature 
protein of 22 kDa, that it is composed of 191 amino 
acids (aa). It is excised from the polyprotein in the 
Prevalence of hepatitis C
                Hight > 3.5%
                Moderate 1.5%-3.5%
                Low < 1.5%
                No data
Figure 1  Hepatitis C virus infection in the World. Analysis of seroprevalence[2].











Figure 2  A model of hepatitis C virus lipoviral particle. Lipid membrane 
formed by low density lipoproteins (LDL) and very low-density lipoproteins 
(VLDL) on the surface of the virion (given in grey). Viral core is given in blue 
and viral RNA is shown in orange. Heterodimers of glycoproteins E1 and E2 
are partially embedded in the lipid bilayer and are forming 6 nm long spikes 
(projections) on the surface of the virion[14-19]. As a result of association with LDL 
and VLDL, the morphology of the virion is not icosahedral. Depending on the 
viral source, the shape and size of the particles might vary.
Table 1  Overview of the size of hepatitis C virus proteins
Protein No. of aa aa position n ref. seq. MW of protein, kDa
Core immature 191     1-191 23
Core mature 174     1-174 21
F protein of ARF protein 126-161 Approximately 16-17
E1 192  192-383 35
E2 363  384-746 70
p7   63  747-809   7
NS2 217   810-1026 21
NS3 631 1027-1657 70
NS4A   54 1658-1711   4
NS4B 261 1712-1972 27
NS5A 448 1973-2420 56
NS5B 591 2421-3011 66
No. of aa: Number of amino acid; MW: Molecular weight; kDa: KiloDalton; ref.seq.: Reference sequence (HCV strain H77 ; accession number NC_0041).
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the viral capsid assembly, the protein also interacts 
with the HCV RNA. Besides that, the core protein poses 
regulatory functions during the RNA translation. Analyses 
of HCV core protein expression indicate that additionally 
it may be involved in several processes in cells such as 
apoptosis, lipid metabolism [HCV-related (mainly gt 3) 
fatty liver] and the development of HCC[29]. Interestingly, 
the core protein can induce the redistribution of LDs by 
the regeneration and the regression of these organelles 
in specific intracellular domains[30]. This phenomenon 
is also linked to the assembly of HCV particles. LDs are 
associated with the HCV core protein at the second 
domain and the interaction seems to trigger steatosis[30]. 
It has been shown, that if the core protein is mutated, 
the association with LDs might be disrupted. A decrease 
of this association has a negative effect on the HCVcc 
production. The HCV core protein was also shown to be 
involved in the Ca2+ regulation[31]. Thus, it is not only a 
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endoplasmic reticulum (ER) by a cellular signal peptidase 
(SP)[26]. An additional cleavage of the immature protein 
results in the mature 21 kDa core protein. The core 
protein contains three domains. The first domain 
spans the N-terminal region of 117 aa (aa 1-117). It 
contains mostly basic residues and there are two short 
hydrophobic regions. This domain is involved in binding 
to the viral RNA. The second domain between the aa 
118 and 174 is more hydrophobic and less basic. This 
domain is engaged in the creation of links with the 
lipid droplet (LD). LDs are intracellular structures that 
are used for the lipid storage (Figure 3C)[18] . The third 
domain is localized between the aa 175 and aa 191 and 
it contains the signal sequence for the ER membrane 
translocation of E1 ectodomain[27]. In vivo, the mature 
core proteins are believed to form homo-multimers that 
are accumulated mainly at the ER membrane and can 
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Genome ss (+) RNA approximately 9.6 Kb
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Figure 3  Hepatitis C virus genome, polyprotein precursor and the initial steps of core assembly in endoplasmic reticulum. A: Being structurally identical, 
the genomes of seven hepatitis C virus (HCV) genotypes demonstrated approximately 30% of sequence diversity[140]. Two non-translated regions (5’- and 3’-NTR) 
are flanking a single open reading frame (ORF) shown in grey; B: Polyprotein precursor composed of about 3000 amino acids translated from a single ORF. Three 
structural proteins - a core protein (shown in blue) and two envelope proteins (shown in green) and seven non-structural (NS) proteins NS1, NS3, NS4A, NS4B, 
NS5A, and NS5B (shown in orange) that are involved in cleavage, assembly, transcription and some other functions are shown. Alternative reading frame protein (ARFP) 
that overlaps with the core protein sequence is given in blue. Serine protease NS2 is given in pale yellow. Transmembrane fragments in non-structural proteins are 
shown as staples; p- phosphoprotein; C: A model of initial steps of the virion core assembly in the endoplasmic reticulum (membranous web is given in dark green) 
on lipid droplet (LD). Polyprotein precursor is cleaved by cellular C-terminal signal peptidase (red arrow) and cellular signal peptidase (blue arrow) to release capsid 
protein. NS3-NS4A serine protease cleaves the remaining proteins, while NS2-NS3 (grey arrow) protease cleaves itself. Pre-assembled cores are transported to the 
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basic structural element of HCV, but it is an active player 
in a significant amount of additional processes, including 
signaling pathways regulation[17,30,31]. 
Envelope proteins E1 (gp35) and E2 (gp70)
Glycoproteins E1 (gp35 kDa, 192 aa long) and E2 
(gp70 kDa, 363 aa long) are type 1 transmembrane 
proteins that are forming the envelope of the virus 
particle (Figures 2 and 3B). E1 an E2 are cleaved from 
the precursor in ER by the cellular SP. The glycoproteins 
contained large hydrophilic ectodomains and 30 aa 
long transmembrane domains (TMD). The TMD is 
responsible for an anchoring of the envelope proteins 
in the membrane of the ER and their ER retention[32]. 
The ectodomains of both glycoproteins are heavily 
glycosylated. The E1 has 4-5 and the E2 - 11 putative 
N-glycosylation sites, respectively. Interestingly, 
the glycosylation sites are rather conserved in each 
genotype[33], but the number of glycosylation sites 
varies between the genotypes. It’s worth mentioning, 
that some of the glycan’s are engaged in folding and 
formation of the E1-E2 heterodimer complexes on the 
surface of the virion. These complexes are essential 
for the interaction with cellular receptors and helps to 
promote the virus-to-cell fusion[34]. 
The HCV E2 contains two hypervariable regions 
HVR 1 and HVR2 which are the most mutable parts of 
the HCV genome. The first 27 amino acids of E2 are 
attributed to the HVR1 sequence. It is suggested that 
a prominent heterogeneity of the region could help the 
virus to evade from the immune system pressure and 
to develop a chronic infection[35]. It is worth mentioning, 
that an infectious clone lacking the HVR1 was still 
capable to infect chimpanzee, but with a largely reduced 
efficiency, thus supporting the HVR1 engagement 
in the cell infection[36]. The HVR2 includes seven aa 
(91-97) and this region was shown to contribute to 
the HCV E2 receptor binding[37]. The high variability of 
the HVRs reflects the exposure of these domains to 
HCV-specific antibodies. In fact, the E2-HVR1 is the 
most frequent target for neutralizing antibodies[38,39]. 
However, the combination of a viral mutation with the 
selective pressure of the humoral immune response 
leads to the viral escape via epitope alterations[40]. 
Moreover, the association of virions with lipoproteins 
and the presence of a glycan shield (possessed by the 
E1-E2 heterodimers), reduce the antibody access to the 
“sensitive” neutralizing epitopes[24,41,42]. This protection 
is representing a serious obstacle on the way to obtain 
broadly neutralizing antibodies.
Non-structural protein NS1 (p7) 
The NS1 (also called “p7”) is a small 63 aa long protein. 
It is located between E2 and NS2 proteins and it is 
linked to both structural and non-structural proteins. Its 
cleavage is mediated by the cellular SP. Interestingly, 
the E2-p7-NS2 precursor can also be detected[43,44]. It 
is suggested, that such a precursor may regulate the 
kinetic of the HCV infection; however, up to now the 
precise role of this protein in the HCV life cycle remains 
obscure. NS1 has two transmembrane domains (TMDS) 
embedded in the ER membrane and the C-terminal 
TMD of NS1 can act as a signal sequence to promote 
the translocation of NS2 to the ER lumen[45]. The 
protein can also form the ion channel which has an 
important role in the HCV infection. This channel can 
be blocked by the antiviral drug[45]. The recent studies 
demonstrate that NS1 acts to prevent the acidification 
which is required for the production of HCV particles[46]. 
In addition, the protein appears to be essential during 
assembly and release of infectious particles as shown 
on different genotypes[47]. Based on that, NS1 may be 
considered as a potential target for new antivirals[48,49].
Non-structural protein NS2 (p23) 
The NS2 is a hydrophobic transmembrane protein of 23 
kDa composed of 217 aa. It is a cysteine protease which 
is required for the HCV infectivity[50]. The N-terminal 
residues of NS2 can form 3 or 4 transmembrane helices 
which are inserted in the ER membrane. The crystal 
structure has been determined. The C-terminal residues 
of NS2 with the 181 aa long N-terminal domain of NS3 
play an important role in the function of the NS2/3 
cysteine protease[51]. The NS2/3 protease is spanning 
from the amino acid 810 to amino acid 1206. It has 
been shown that the NS3 zinc-binding domain could 
stimulate the activity of the NS2 protease[52]. The well-
known function of NS2 is the auto-cleavage at the NS2/3 
site[53]. Oem et al[53] suggested that the expression of 
HCV NS2 results in the up-regulation of the fatty acid 
synthase transcription. In fact, this may implicate the 
role of NS2 in the prompting HCV induced steatosis[54]. 
There data are in favor of the protein engagement in the 
viral assembly and release[54].
Non-structural protein NS3 (p70) 
The NS3 is a 70 kDa protein composed of 631 aa. 
It is cleaved at its N-terminus by the viral NS2/NS3 
autoprotease. The C-terminal part of NS3 (442 aa) has 
an ATPase/helicase activity, and it catalyses the binding 
and unwinding of the viral RNA genome during the 
viral replication[55,56]. The N-terminal part (189 aa) of 
the NS3 protein has both serine protease and NTPase 
activities[56]. The NS3 along with the non-structural 
protein NS4 is involved in cleavage of the NS3/4A, 
NS4A/4B, NS4B/5A and NS5A/5B junctions[57,58]. A direct 
interaction between NS3 and NS5B is mediated through 
the protease domain of NS3. It is suggested, that these 
proteins may act together during the HCV replication[59]. 
The HCV protease NS3/4A can also cleave some cellular 
targets involved in the innate immunity, such as MAVS 
(an antiviral signaling protein), which can indirectly 
activate the nuclear factor-kappa B (NF-κB) and the 
IFN regulatory factor 3 to induce type Ⅰ interferon[60,61]. 
The protein NS3/NS4A can interfere with the adaptive 
immunity. In addition, the NS3/NS4A protease is 
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essential for the viral infectivity, thus, it is a promising 
target for antivirals[61-64]. In 2011, two potent NS3/NS4A 
inhibitors, boceprevir[61] and telaprevir[62] were approved 
by FDA and EMA and were used in combination with IFN 
α and ribavirin. However, several resistance-associated 
mutations within the NS3/NS4A coding region have 
been observed. 
Non-structural protein NS4A (p8)
The NS4A is an 8 kDa proteins that is composed of 54 
aa. As indicated above, it is a co-factor required for the 
NS3 protease activity. The N-amino-terminal domain of 
NS4A is hydrophobic and the deletion analysis shows 
that NS4A was required for the ER targeting of NS3[65-68]. 
In addition the NS4A interaction with NS5A is essential 
for the phosphorylation of NS5A[68]. Besides its important 
role in HCV replication, NS4A can also contribute to 
the viral pathogenesis by influencing some cellular 
function[66]. Interestingly, NS4A was detected not only 
on the ER, but also on the mitochondria either alone or 
together with NS3 in the form of NS3/4A polyprotein. 
It has been shown, that the NS4 expression altered the 
distribution of mitochondria and caused damage which 
leads to the host cell apoptosis[66].
Non-structural protein NS4B (p27)
The NS4B is a 27 kDa protein of 217 aa. It has four 
membrane spanning domains which are important in 
recruitment of the other non-structural viral proteins[68]. 
By electron microscopy, it has been shown, that NS4B 
induced a tight structure termed “membranous web”. 
All viral proteins were found to be associated with this 
membranous web that formed a viral replication complex 
(“factory”) in HCV infected cells[67]. The polymerization 
activity and lipid modification of NS4B are important 
for the induction of the specialized membrane structure 
involved in the viral RNA replication[68,69]. NS4B is likely 
not engaged in the virus replication, but may contribute 
to the assembly and the release of the virus particles[69].
Non-structural protein NS5A (p56/p58) 
The NS5A is a 56 kDa phosphoprotein of 485 aa (Figure 
3). In HCV infected cells, the protein is present in two 
differently phosphorylated forms: phosphorylated 
(56 kDa) and hyper phosphorylated (58 kDa). NS5A 
is multifunctional and it contributes to the HCV 
replication, virus pathogenesis, modulation of cell 
signaling pathways, virus propagation and the interferon 
response[70,71]. The N-terminal amphipathic helix of the 
NS5A protein is conserved in different genotypes and it is 
necessary for the membrane localization[72-76]. Mutations 
in NS5A enhanced the capacity of the sub genomic HCV 
RNA replication in cell culture systems[77]. It was shown 
that the N-terminal part of NS5A contained a new zinc-
coordination motif which affected the HCV replication[70]. 
NS5A has a potential role in mediating the IFN response. 
It contains a so-called “interferon-α sensitivity-
determining region” (ISDR, aa 237-276)[78]. ISDR can 
be used to predict the resistance and the sensitivity of 
HCV to the IFN treatment. NS5A was also showed to be 
associated with a variety of cellular signaling pathways 
including apoptosis[70]. NS5A is already used as a target 
for the direct acting antivirals.
NS5B protein (p66-68)
The NS5B is a 591 aa long protein and it is located at the 
C-terminus of the precursor. NS5B is a RNA-dependent 
RNA polymerase containing the GDD motif in its active 
site[79]. The NS5B initiates synthesis of the HCV negative-
strand RNA. The crystal structure of NS5B showed a 
typical ‘right hand’ polymerase shape with finger, palm 
and thumb sub domain. Since NS5B lacks the “proof-
reading’’ function[79], numerous mutants might be 
generated during transcription. Because of its key role in 
the virus replication, the NS5B protein is considered as a 
potential target for the antiviral drug[80].
F protein, ARFP
In addition to ten proteins described above, the 
frameshift (F) or alternate reading frame protein (ARFP), 
or “core+1” protein has been reported[81-83]. The ARFP 
is the result of a -2/+1 ribosomal frameshift between 
codons 8 and 14 of the adenosine-rich region encoding 
the core protein. ARFP ends have different stop codons 
depending on the genotype. Thus, its length may vary 
from 126 to 161 amino acids. In the case of genotype 
1a, the protein contains 161 amino acids. However, 
the situation with ARFP is more complicated, since 
alternative forms of this protein such as ARFP/DF 
(double-frame shift) in genotype 1b, and ARFP/S (short 
form) were recently described[83]. ARFP is a short-living 
protein located in the cytoplasm[84] in associated with 
the endoplasmic reticulum[85]. Detection of anti-ARFP 
antibodies in sera of HCV-positive subjects indicates 
that the protein is expressed during infection[86], but is 
likely not involved in the virus replication. Some findings 
suggested engagement of ARFP in the modulation of 
dendritic cells function and stimulation of the T cell 
responses[87]. The implication of ARFP in the viral life 
cycle remain to be elucidated.
HCV TRANSMISSION ROUTES
The HCV in blood and blood products is the main source 
of infection. However, the transmission routes of HCV 
might be different and ountry dependent. The iatrogenic 
transmissions are: the blood transfusion of unscreened 
products[88], the transfusion of clotting factors or other 
blood products[89,90], the organ transplantation, the reuse 
of medical instruments used in invasive settings (e.g., 
needles, infusion sets, syringes, catheters) in Egypt 
before 1985, hemodialysis, endoscopy, intravenous drug 
use[91-95]. The sexual way of transmission is controversial. 
Nevertheless, the risk may increase when favoring 
conditions such as sexually transmitted infections, the 
frequencies and the type of sexual activity are taking 
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place[94-101].
The rate of HCV mother-to-child transmission is about 
4.3%, but it is much higher, 22.1% among the human 
immunodeficiency virus (HIV) co-infected mothers[102,103]. 
The mother-to-child transmission generally occurs at 
delivery, but also in utero, if associated with high risk 
factors, such as high maternal HCV RNA levels and/or 
HIV co-infection. Interestingly, vaginal vs cesarean 
section delivery, amniocentesis and breast-feeding did 
seem to increase the transmission risk[102-108]. Because 
of a passive transfer of anti-HCV antibodies at, or after 
18 mo of ages, perinatal transmission diagnosis as 
serum HCV RNA and/or anti-HCV antibodies should be 
performed twice in infants (6 mo and 1 year of age)[109] 
during this period, as recommended by the European 
pediatric HCV network[110]. It should be emphasized, that 
the INFL3 CC (IL28B) genotype is likely associated with 
a spontaneous clearance of the HCV genotype 1(gt1) 
infection[104].
According to the World Health Organization, thou-
sands of new cases of the HCV infection (as a result of 
an occupational exposure via skin injury), are registered 
annually[111]. Most of these cases occurred during 
surgery in emergency departments, and routine medical 
procedures[112]. Seroconversion rates in infected individuals 
are ranging from 0% to 10.3% (+/- 0.75%)[113,114]. For 
instance, after accidental needle stick, seroconversion 
rate was reported as 1.8%[115]. During a 5-year period 
(2008-2012), a total of 16 HCV outbreaks resulting in 
160 outbreak-associated cases and more than 90000 at-
risk persons notified for screening were reported by the 
Centers for Disease Control (CDC) and Prevention[115]. 
Among dentists[116] and surgeons[117], an eye protection 
should be reinforced because of possible HCV transmission 
by splashes of blood and other body fluids[117]. Cosmetic 
procedures and/or acupuncture, as well as circumcision 
are extensively associated with HCV transmission, 
but the risk seems to be small[118,119]. Lacking of sterile 
techniques and/or nonprofessionally performed tattoos or 




The HCV genome demonstrated a prominent genetic 
diversity. Seven genotypes (gt 1-7) and 67 subtypes 
(a, b, c, etc.) have been described. The genotypes are 
characterized by a distinct geographic distribution and 
clinical manifestations[127,128]. For example, the genotype 
1 is prevalent in Americas, Japan and Europe[129]. 
Indeed, the HCV genotype prevalence also differs 
according to the transmission route and the age of 
infected individuals. For instance, the HCV gt 3a and 1a 
are highly represented among intravenous drug users 
and the HCV gt 1b is frequent among patients who 
received blood transfusions[130-134]. In Japan, the HCV gt 
1b is the most prevalent[1] while, the infected population 
is generally older than in the United States[2], and an 




The HCV entry initiates the viral replication cycle. Virus 
that is a complex and multi-step process that is not 
completely understood. However, the main principal 
steps and the principal cell surface interaction partners 
are known. At least, four cellular entry factors and two 
specific receptors are required for a successful virus 
entry (Figure 4). Since many interactions should take 
place, the binding to the cell surface is a relatively 
slow process which should be well coordinated[135-141]. 
The initiation of HCV entry seems to be similar to that 
of many other viruses, that utilize for attachment the 
glycosaminoglycans (GAGs)[141]. Earlier, it was proposed 
that E1 and E2 are involved in these interactions[141]. 
However, the HCV particle interacts with lipoproteins and 
in this regard, it is more likely that the apolipoprotein 
E is responsible for the interaction with GAGs[141]. 
Furthermore, due to the nature of the viral lipoprotein 
particle, it was proposed that the LDL receptor is required 
in the initial stage of attachment. However, this interaction 
leads the particle to a degradation pathway[141]. After 
the completion of docking, the viral particle interacts 
with specific cellular receptors. It was shown that the 
envelope glycoprotein E2 interacts with two receptors 
a scavenger receptor B1 (SR-B1), and with CD81 
(tetraspanin family protein -TSPAN28)[142-144]. It is likely, 
that interaction of HCV with SR-B1 comes first[142]. In 
this regard, it remains to be determined whether SR-B1 





Figure 4  Attachment factors, receptor and entry factors utilized by hepatitis 
C virus. At least six membrane proteins are essential for the virus attachment and 
entry. Heparan sulfate proteoglycan (HSPG) - a type of glycosaminoglycan (GAG) 
and low density lipoproteins (LDL)-receptor that is promoting the LDL endocytosis 
are considered as binding factors for hepatitis C virus (HCV). Scavenger Receptor 
class B member 1 (SR-B1) and CD81 that are ubiquitously expressed on the cell 
surface, are considered as true receptors. The receptor–viral cargo complex is 
then moving to the cell-cell contacts (not shown), where the interaction with the 
tight-junction proteins Claudin 1 (CLDN1) and Occludin (OCLN) takes place. Both 
proteins are required at the late stage of the entry. Additional interaction partners 
that are likely engaged in the HCV entry are described in the text. The docking of 
the LVP to the cellular membrane is shown.
Morozov VA et al . HCV: Morphogenesis, infection and therapy
193 February 27, 2018|Volume 10|Issue 2|WJH|www.wjgnet.com
and CD81 form a complex that facilitates the entry. 
It is noteworthy that the interaction with CD81 alone 
can activate signaling pathways that may be important 
for the viral infectious cycle[141] and the interaction 
between CD81 and the E2 glycoprotein appears to 
be essential for initiating the adsorption[141]. Next, the 
receptor complex with attached virion is moving to the 
tight junction, where the interaction with the proteins 
claudin-1 (Cldn1) and occludin (OCLN) is likely taking 
place. However, there is no experimental evidence 
indicating a direct interaction between the viral particle 
and the tight junction proteins. Thus, these proteins 
cannot be considered as classical receptors. Finally, 
other cellular factors such as epidermal growth factor 
receptor[145] and the Niemann-Pick C1-like 1 cholesterol 
uptake receptor[146] are likely involved in the HCV entry. 
It has been shown that CD81 and Cldn1 proteins may 
interact with the surface of hepatocytes[147], suggesting 
that CD81-Cldn1 form a complex that is implicated in 
the HCV entry. Although the tight junction proteins are 
involved in the HCV entry, the role of cell polarization 
in viral entry remains controversial. Interestingly, a 
live imaging of the fluorescent HCV particle in Huh7.5 
cells showed that the particle was first attached on 
filopodia and then migrated towards the main body 
of the cell using presumably an actin-dependent 
transport mechanism[148]. It is important to note that 
the hepatocyte is a polarized cell with multiple apical 
and basolateral poles presenting a unique organization 
that is observed only in the liver. Another characteristic 
of HCV is its ability to spread by cell-to-cell contacts[149]. 
The essential role of the E1, E2 transmembrane domains 
in the viral entry[150] and the involvement of different 
regions of the ectodomain of E2 in the viral assembly 
were demonstrated[151]. It has been shown that glycans 
on the envelope proteins may be involved in different 
stages of the viral infectious cycle[42,152,153]. Furthermore, 
the N-linked glycan shield of the viral glycoproteins is 
essential to protect against the neutralization of the virus 
by antibodies[154]. 
An additional interaction partner of the CD81 
receptor, called “EWI-2wint” was identified[155]. It was 
demonstrated that EWI-2wint is a natural inhibitor of 
the HCV entry, which by an interaction with the CD81 
receptor can prevent CD81-E2 interaction. Later on, the 
regions involved in the interaction between CD81 and 
EWI-2wint were identified[156] and studies in living cells 
at a single molecule level proved that EWI-2wint reduces 
the mobility of CD81 at the plasma membrane[157,158]. 
Finally, it was reported that the enrichment of the 
plasma membrane in ceramides has an inhibitory effect 
on the viral entry[159]. 
Post-entry events
It was shown by a traffic monitoring that after binding to 
the cells surface, the virus particles enter into the cells 
using clathrin dependent endocytic pathway[160,161]. The 
viral particles are transported to the early endosomes 
expressing RAB5A where the merger took place. This 
process requires an acidification of the compartment[162]. 
The virus capsid is then released and destroyed, while 
the viral RNA is released to the cytoplasm. The RNA 
is used for both processes the replication and the 
polyprotein translation (Figure 5). The RNA translation 
occurs in the endoplasmic reticulum (ER) and it is 
initiated by a binding of the 5’UTR IRES to the ribosome. 
The primary translation product is approximately 3000 
amino acid long polyprotein precursor which contains 
structural and non-structural proteins of the HCV. Then, 
the polyprotein is cleaved by the host and viral proteases 
into structural and non-structural proteins. 
Several studies evidenced that the HCV infection 
results in ER stress and autophagy responses and that 
HCV can regulate the autophagy pathway. In fact, the 
autophagy machinery is required to initiate the HCV 
replication and suppression of autophagy inhibits this 
process[163-171]. Interestingly, it has been demonstrated 
that HCV induces autophagosomes via a Class Ⅲ
PI3K-independent pathway and uses autophagosomal 
membranes as sites for its own RNA replication[171]. For 
the HCV RNA replication, polarized positive HCV RNA 
genome synthesizes a negative strand by the NS5B 
RNA-dependent RNA polymerase. The newly synthesized 
negative RNA strand may further act as a template to 
synthesize the positive strand of the viral RNA[172,173].
Viral assembly and release
A assembly of the virion is another multi-step process 
and certain steps of it remains obscure. It is known that 
the particle assembly occurs within the ER in a close 
proximity or directly on the surface to LD[170] (Figure 
5). After the proteolytic cleavage of the polyprotein 
precursor, NS5A initiates the early phase of the viral 
particle formation by the interaction with the core protein 
and its C-terminal serine cluster determines the NS5A-
core protein interaction[174].
The viral RNA released from the viral core is recruited 
to the replication complex within the membranous web. 
The HCV RNA-dependent RNA polymerase (NS5B) has 
no proofreading mechanism to correct errors during 
the strand synthesis. This propensity for error during 
replication results in an accumulation of the HCV 
quasispecies, those are closely related, but genetically 
somehow distinct. The newly synthesized positive-
sense viral RNA is transported to the site of the core 
assembly and is encapsulated. However, the mechanism 
that engaged in RNA delivery to the capsid during 
assembly is not known. The nucleocapsids with RNA are 
presumably enveloped by budding into the lumen of the 
ER. So, after the nucleocapsid formation, it is associated 
with the envelope protein forming an immature 
particle and secreted from cell through the cytoplasmic 
membrane[173,174]. However, it remains unclear how 
the coupling with lipoproteins and apolipoproteins is 
regulated, since the pattern of lipoproteins on the virus 
particle might differ significantly. Next, the virions are 
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transported through the Golgi compartment to finalize 
the maturation. Recently, it has been shown, that HCV 
can induce the fragmentation of Golgi[175]. Thus, it might 
be another important indication of the virus-induced 
pathogenesis. However, if the fragmentation of Golgi is 
significant, it may cause not only destructions of Golgi, 
but also provoke the cell death. Definitely, it might be 
not advantageous for the virus. It cannot be excluded, 
that this phenomenon might take place predominantly 
during the active replication of the virus. In this regard, 
it might be useful to investigate the HCV-induced Golgi 
destructions, as a possible trigger of liver necrosis. 
Virus release and extracellular particles
The detail mechanism of the HCV release requires 
more comprehensive investigation. It is well established 
that secretion of the HCV particle depends on both the 
VLDL and the apolipoprotein (apoB) presence[176-187]. 
So, when the maturation is finished, the virions are 
transported to the plasma membrane using the VLDL 
pathway[145]. Particles isolated from cell-cultures and 
from patient sera are pleomorphic, immature and most 
of them are non-infectious[170]. In this regard, in the 
virus preparations from human plasma examined by 
electronic microscopy (EM), it was difficult to reveal 
“perfect” mature particle[170]. The association with 
fragments of cellular membranes (or other cellular 
debris) and/or an irregular lipoprotein content might be 
the reasons of the problem. Anyhow, it is evident, that 
a classical “assembly-maturation-release” processing 
line of HCV is facing problems. A diverse buoyant 
density of infectious particles is reflecting the problems. 
The analysis of LVP from plasma by sucrose gradient 
centrifugation demonstrated, that the buoyant density 
of the virus-contained fractions is diverse (1.10 g/mL to 
1.16 g/mL)[170]. Positioning of virus-containing fraction 
on the gradient depends on the initial material that 
was used for the virus isolation. The infectious particles 
isolated by isopicnic centrifugation from cell-culture 
were mostly present in the fraction with a density 1.14 
g/mL and examined by cryo EM, when were about 60 
nm in diameter[170]. Significantly more virus-associated 
cellular impurities including lipoproteins, are associated 
with viruses isolated from patient sera and that influence 
the virus density and the particles are significantly less 
dense[177,178]. It is considered that the observed density 





























12. Suggested HCV release in MVs













Figure 5  Schematic representation of the hepatitis C virus life cycle. (1) The lipoviral particles (LVP) binds to entry factors and receptors on the surface of 
hepatocyte; (2) The virus enters into the cell by a clathrin-mediated endocytosis; (3) Transportation of the virus in endosome; (3) Acidification of endosome, un-
coating of the virion and dissociation of the viral core; (4) Release of the viral RNA; (5 and 6) Translation and replication of the viral RNA in the ER in the convoluted 
membrane structure called the membranous web (shown in dark green); (7) Cleavage of the protein precursor by cellular and viral proteases, assembly of the core 
on the surface of the lipid droplet (LD) and recruitment of the newly synthesized viral RNA to the viral core during the formation. The mechanism of the viral RNA 
recruitment to the site of the assembly is not known. It is also unclear whether the core maturation is finalized at this stage; (8) The viral nucleocapsid egresses into 
the lumen side of the ER, likely interacted with very low-density lipoproteins (VLDL) and translocated to Golgi. It is not clear if some VLDL-free particles can also 
be produced (?). Details of traffic machinery are not well defined; (9) Final maturation of viruses in Golgi and virus induced partial fragmentation of Golgi; (10) The 
hepatitis C virus (HCV) complex with VLDL is directed to the plasma membrane using the VLDL secretory pathway; (11) Release of particles from the cell (adapted 
from Ref.[16,19,135]); and (12) The HCV release in MV cannot be excluded as another pathway for the virus release during active replication.
Golgi
MV
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fluctuation is a result of irregular content of lipoproteins 
tightly associated with virion. In fact, this diversity might 
have an additional reason. It cannot be excluded that in 
vivo the virus particles might in addition be transported 
by extracellular vesicles. In fact, the size of putative 
transporters might be large enough to carry not a single, 
but numerous viral particles. For example, membrane 
derived microvesicles (MVs) can be 500-1000 nm in 
diameter, so as large as lipid droplets[184,185]. MVs are 
present in the fractions of different densities, indicating a 
diversity of diameter and/or cargo[186].
Analysis of cell supernatant by gradient density 
centrifugation demonstrated that the MVs subpopu-
lations are different, depending on the cell line. It is 
known, that MVs are intensively released by primary 
hepatocytes and immortalized cells of hepatic origin[186]. 
The release from hepatocytes might be increased by an 
undergoing lipotoxicity[187]. Thus, MVs are actively used 
by the hepatocytes as delivery system and the amounts 
of MVs might be increased in response to lipotoxicity and 
likely other complications. In this regard, we speculate 
that during acute phase of infection (or high rate of 
replication) the virus can trigger the MV release and that 
might be an additional pathway for the virus. How MVs 
containing virus particles can influence HCV distribution 
along the density gradient? In fact, MV containing 
different amount of viruses may contribute to observed 
diversity of buoyant densities of HCV, especially when 
plasma (or serum) is investigated.
It is known, that the diffusion of spherical particle 
through a viscous liquid is dependent on the particle 
diameter. It is described by Stokes-Einstein equation:
D = 
D = diffusion constant, k = Boltzmann constant, T 
= temperature (K), η = solvent viscosity, r = radius of 
spherical particle. 
Another parameter that influences the diffusion is 
the mass of spherical particle and the equation counting 
these parameters looks as follows: 
nD = 
where: D = diffusion; α = radius of the spherical 
particle; M = mass of the particle; η = viscosity of the 
medium.
So, the diffusion of a spherical particle is decreased 
with the increase of diameter and mass. Thus, if MVs 
besides the regular cargo (mRNA, miRNA, modulators, 
peptides, proteins ) have in addition a different particle 
load, it might explain why MVs of the same sizes might 
be recovered in fractions with different densities, and 
vice versa. Thus, when supernatants (or plasma) are 
examined by density gradient centrifugation, MVs of 
different size and different virus loaded, can increase 
the amount of virus-containing fractions. The expected 
distribution of lipoproteins, LVP from human plasma 
in a sucrose gradient and the suggested positioning of 
MVs with different virus load are given below (Figure 6, 
adapted from[170] with modifications). 
What might be the advantage, for the virus to use 
the MVs secretory pathway? Since the MV are released 
by budding from the plasma membrane, it allows the 
virus to acquire additional protection from the “rough 
environment”. Second, if MV is loaded with numerous 
particles, it might be the way to increase the probability 
of a successful infection of distant cells by creating a 
high “local MOI” after MV distruction. That effect might 
be even more prominent, if the MV loaded with viruses 
would be endocytosed by the cell. We suggest, that 
the MV pathway might be used during active virus 
replication of the virus. The possible implication of MVs 
for the virus delivery might be interesting to investigate 
using in vitro models.
MODELS TO STUDY HCV
The progress in HCV research is completely dependent 
on model systems[188]. The most frequently used models 
(Figure 7) for investigation of HCV are described below.
HCV replicon systems
The HCV genome was identified in 1989 by cloning it 
from infected chimpanzee, while in humans the amounts 
were too low for detection[189]. The first complete full-
length HCV cDNA clone was constructed from the HCV 
strain H77 (genotype 1a). The HCV RNA transcribed from 
this clone was found to be infectious after intrahepatic 
injection in a chimpanzee. The HCV viremia was detected 
at week 1 and increased from 1 × 102 genomes/mL to 1 
× 106 genomes/mL at week 8[190,191]. Then, several full-
length HCV RNAs were synthesized and were shown 
to be infectious in chimpanzees[190-193]. However, these 
HCV clones were found to replicate inefficiently in 
vitro. This limitation was resolved by the group of Prof. 
Ralf Bartenschlager, when subgenomic HCV replicon, 
cloned from the HCV genome was constructed[73]. After 
transfection of this subgenomic clone into the Huh7 cells, 
it was found that in drug-resistant cells a high-level of 
the HCV RNA replication occurred. The replication of 
the HCV subgenomic replicon was confirmed in several 
cell lines, but the hepatocarcinoma cell line Huh7 was 
the most permissive. The interferon treatment of the 
replicon inoculated Huh7 cell clones, made them more 
permissive to support both subgenomic and full-length 
HCV replication, (these so-called cured cell lines are 
Huh7.5 or Huh 7.5.1 cells)[15,194]. Afterwards, several 
studies demonstrated that the virus and host factors 
were important for the HCV replication in cells. Some 
mutations in the wide-type (wt) consensus sequence 
efficiently enhanced the HCV replicon replication, some 
mutations in the non-structural protein efficiently 
contributed to the replication and the adaptation to the 
host cells[195-198]. The mechanism of improved replication 
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these replicons with adaptive mutations could replicate 
with a high efficiency, they were not able to produce 
infectious particles in vitro.
This problem was solved with development of the 
genotype 2a infectious clone JFH-1. A selectable HCV 
replicon was constructed containing the full-length HCV 
cDNA and showed to produced infectious particles in 
vitro and in vivo[199]. Based on this infectious clone, 
several different genotypes chimeric clones (genotype 
1a, 1b, 2a and 3b) where the non-structural genes have 
been replaced by those of JFH-1 were constructed and 
were shown to be infectious in Huh-7 cells. The most 
efficient construct is the genotype 2a/2a clone which 
consists of J6CF and JFH-1 derived sequence[200]. The 
HCV replicon is remarkably valuable for studying the 
HCV replication and for testing of new antiviral drugs. 
The HCV subgenomic replicons containing reporter 
genes (luciferase, secreted alkaline phosphatase and 
chloramphenicol transferase) facilitated the study of 
the HCV infection. This high-throughput screening 
assay allowed the visualization and tracking of the HCV 
replication complex in living host cells without affecting 
the HCV replication[47,201].
HCV pseudotype virus particles 
The HCV pseudotyped particles were constructed with 
chimeric genes expressing HCV (genotype 1a) envelope 
E1 and E2 proteins (HCVpp) and the transmembrane and 
cytoplasmic tail of vesicular stomatitis virus G protein. 
The pseudotyped particles allowed a detailed study of the 
role of HCV receptors in the early steps of HCV infection 
(adsorption, and viral entry) in Huh7 cells and primary 
human hepatocytes[202-204]. The system is useful for 
testing of new antiviral drugs[203].
The HCV subgenomic replicon and the HCV 
pseudotyped particles (HCVpp) have markedly 
improved studies on the HCV infection. However, 
the high replication rate in cells was not correlated 
with amount of released infectious virions. However, 
the main disadvantage of these in vitro systems is 
that the viruses released from these cells are not 
infectious. The major reason of that might be that 
the adaptive mutations enhancing HCV replication 
rates are deleterious for HCV particles assembly and 
release. The problem was solved when a genotype 
2a subgenomic replicon was established in the Huh-7 
cell lines. It contained a full-length genotype 2a clone 
JFH-1 derived from serum of a Japanese patient with 
fulminant hepatitis. The replication rate was about 20 
times greater than Con1 (gt1b) when transfected into 
Huh-7 cells. In addition, this replicon could replicate 
efficiently without amino acid mutations[47]. In 2005, 
Wakita et al[200] continued to transfect this JFH-1 clone 
into Huh-7 cell lines and found high levels of intracellular 
HCV RNA replication and protein expression. By means 
of passages in infected cells, they demonstrated that 
JFH-1 transfected cells had continuous HCV replication. 
In this study, it was also shown, that the HCV viral 
particles (HCVcc) secreted in the culture supernatant 
had a density of approximately 1.15-1.17 g/mL. The 
released particles have a spherical morphology and a 
diameter of about 55 nm. The JFH-1 infectivity could 
be neutralized by anti-CD81 antibody, suggesting the 
important role of CD81 in HCV entry. In addition it 
was found that the secreted particles could also infect 
chimpanzee[191]. Later, several groups observed that 
JFH-1 could efficiently infect and replicate without 
adaptive gene mutation in different cell types and HCV 
infectious particles could be produced in the culture 
supernatant[25,199,205-209]. Zhong et al[192] established 
a robust highly infectious in vitro system with JFH-1 
and Huh-7.5.1 cells. The advantage of this model, 
compared to that established by the group of Prof. 



































Figure 6  Putative distribution of lipoproteins (LDL, VLDL, HDL), lipoviral 
particles and viral cores after density gradient centrifugation of plasma 
from infected individual. The picture is based on the known buoyant densities 
of analyzed elements[15,170,184-187]. The density values (g/mL) are given on the 
left. The initial material that has been used for the virus isolation, contributes 
greatly to the associated lipid content of the virions and, as a consequence, 
it influences the buoyant density[177,183-187]. Because of an irregular protein to 
cholesterol amounts, high density lipoproteins (HDL) of 5-15 nm in diameter 
can be detected in the different fractions (1.06-1.21 g/mL). The family of HDL 
is given as dark blue spheres. The buoyant density of microvesicles (MVs) 
may vary from 1.02 g/mL to 1.16 g/mL, depending on MVs diameter and cargo 
(miRNA, tRNA, fragments of mRNA and proteins). If hepatitis C virus (HCV) 
is released in MVs with similar diffusion parameters (size and mass), the 
buoyant density of vesicle should be viral cargo-dependent. Fractions 1: Single 
cellular or viral proteins “floating” on the surface, very low-density lipoproteins 
(VLDL, diameter 50-75 nm, density 0.95-1.006 g/mL); Fraction 2: Low density 
lipoproteins (LDL, diameter 18-25 nm, density 1.019-1.06 g/mL) and virus-
free MVs with a low cellular cargo content; Fraction 3: MVs that carry few viral 
particles, possible overlap with LDL and HDL; Fraction 4: MVs with a higher 
viral load, possible overlaps with HDL and with densely loaded virus-free MVs; 
Fraction 5: Lipoviral particles (LVP, diameter 60-80 nm, density 1.10-1.16 g/mL) 
and MVs with a significant viral and/or mixed load. Overlaps with HDL, virus-
loaded MVs and “dense” virus-free MVs are possible; Fraction 6: Lipid-free 
virions with attached immunoglobulins, possible overlap with HDL; Fractions 7: 
HDL with a high protein load; Fraction 8: Non-enveloped viral cores that might 
overlap with dense HDL. Small grey spheres - VLDL. Light blue spheres - LDL. 
Orange arrows indicated fractions of the gradient that are most likely to contain 
viruses and viral cores.
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passages without losing of infectivity. Although JFH-1 
in vitro system provides a powerful tool to study anti-
viral drugs and vaccines, it has some limitations: HCV 
JFH-1 derived from an exceptional case of HCV-related 
fulminant hepatitis belongs to genotype 2a which is not 
the dominant genotype worldwide. That is why since 
2005, different chimeric JFH-1 clones were constructed 
to transfect Huh-7.5 cells, based on intergenotypic 
genotype replicons such as J6/JFH-1 (genotype 2a/2a), 
S52/JFH1 (genotype 3a/2a) and sa13/JFH-1 (genotype 
5a/2a)[209,210], but they are less infectious than HCV 
JFH-1. The reason why JFH-1 is more permissive to 
Huh-7.5 cell lines than other genotypes is still not fully 
understood. In summary, the HCVcc model allowed 
to understand the entire life cycle of HCV and that 
serves as a background for development of numerous 
antivirals[211].
Animal models
Chimpanzee could be a good model to study the HCV 
infection[194,212]. However, these animals are rare, difficult 
to handle, very costly and limited in their use by ethical 
issues[212]. Few data obtained using chimpanzee model 
indicated a specific immune response at the acute 
phase of infection, resulting in inconsistent specific 
neutralization and viral eradication.
Tupaia (Treeshrew, Anathana ellioti) is potentially 
a good model to study the HCV infection, but the 
instability of the infection and its low level limit the use 
of these animals.
The immunotolerized rat model supports the HCV 
replication. Histological and biochemical evidence of 
infection were present, but viremia was relatively low as 
compared with viral load in humans[188].
Mouse models compared with other animal models, 
have some advantages, such as producing animals in 
a short time (short gestation period), lower breeding 
cost and their small size making them easy to mani-
pulate[188,213-217]. Heterotopic liver graft mouse model 
seemed to be suitable to evaluate the putative effect of 
anti-HCV drugs, but the short and low viremia and loss of 
the liver graft were limiting factors. Hepatic repopulation 
mouse model as the chimeric urokinase-type plas-
minogen activator/severe combined immunodeficient 
disorder mouse model has many similarities to human 
systems, and so is the most successful small animal 
model for HCV infection. The main limitation of the model 
is the absence of a normal immune system, which may 
be overcome by combining the model with a human 
hemato-lymphoid system, the value and reproducibility 
of which has yet to be established[218].
A mouse combined human immune system/human 
liver chimeric Rag2-g(c) model was developed in order 
to study immune system and liver pathogens. This ‘Hu-
HEP’ model was used to study hepatocytes derived 
from human induced pluripotent stem cells. The main 
limitations of these models are the low number of 
animals that can be generated and the high cost[219-221].
Recent study demonstrated that hepatocyte-like 
cells differentiated from human embryonic stem cells 
and patient-derived induced pluripotent stem cells 
could be engrafted in the liver parenchyma of immune-
deficient transgenic mice carrying the urokinase-type 
plasminogen activator gene driven by the major urinary 
protein promoter. This efficient engraftment and in vivo 
HCV infection of human stem cell-derived hepatocytes 
provide a model to study chronic HCV infection in 
patient-derived hepatocytes, action of antiviral therapies, 
and the biology of HCV infection[222-225]. 
In vitro models
Established human hepatocarcinoma cell line Huh-7 
and its derivatives support the HCV replication. 
However, as every transformed cell line, they resemble 
the primary cells only partially. Thus, results of experi-
ments performed on these cells might not be always 
appropriated[222].
The primary human hepatocytes and human fetal 
hepatocytes are more clinically and physiologically 
relevant. Thus, they are used to test the susceptibility of 
HCV to drugs and drug-metabolizing enzymes. Another 
in vitro model, the micropatterned co-cultures of primary 
human hepatocytes surrounded by a supportive stroma 
that expressed all known HCV entry factors. The cells 
could be infected by HCV pseudotyped particles and 
HCVcc, albeit with low viral titers. Using this method 
in combination with the highly sensitive luminescence-
based and fluorescence reporter systems, the efficiency 
of anti-HCV therapeutics has been evaluated[222].
Recent studies show that both embryonic[223] and 
induced pluripotent[224,225] stem cells can be differentiated 
into hepatocytes, that are phenotypically similar to 
Established
cell lines
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Figure 7  In vitro, ex vivo and in vivo models to study hepatitis C virus.
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human fetal liver. Study of genetic defects that impact 
the HCV infection could be performed in a human iPS-
derived hepatocyte-like cell-based model[225]. Induced 
human liver-like cells supported the entire life cycle of 
HCV genotype 2a reporter virus. Produced infectious 
particles were able to infect HuH-7.5 cells and secretion 
of TNF-α, and IL-28B/IL-29 was detected in cell culture 
supernatants. Thus, the evaluation of antiviral drugs 
using these cells was possible[222]. 
Ex vivo model
Analysis of precision-cutting adult human liver slices from 
infected or non-infected individuals represents another 
promising model. In fact, this model allowes to maintain 
the tridimensional structure of liver and analyse gene 
and protein expression.It is worth mentioning, that 
using this model, it was demonstrated for the first time, 
the ability of primary isolates (as well as JFH-1, H77/
C3, Con1/C3) to undergo de novo viral replication with 
the production of high titer infectious virus. Thus, this 




The HCV causes damage to the liver cells, but the 
exact mechanism of this phenomenon is unknown.
It is believed, that the damage is largely mediated by 
the host immune response. In immunocompetent and 
immunocompromised patients with little, or no intra-
hepatic damage, including inflammation, high levels 
of the HCV replication have been reported[133,228,229]. 
In about 30% of HCV liver transplanted patients, 
despite the high levels of HCV replication, a recurrent 
hepatitis is developed one year after transplantation [230]. 
However, high levels of an intrahepatic HCV replication 
are usually tolerated by the host immune system. A 
lympho-mononuclear infiltrate represented mainly by 
CD8+ T cells expected to play a major role in the viral 
containment, though other subsets, such as CD4+ T and 
natural killer (NK) cells, and regulatory T cells (Treg) 
are considered[231]. The intrahepatic CD4+ and CD8+ T 
cells can recognize HCV structural and nonstructural 
antigens[232,233]. However, why in most patients the 
immune response cannot resolve the infection remains 
obscure. In fact, cytotoxic CD8+ T cell-mediated killing 
could be blunt by a predominant Treg response[234].
The liver fibrosis is caused by inflammatory cells 
of the intrahepatic infiltrate secreting cytokines and 
chemokines to activate hepatic stellate cells (HSC) 
to secrete collagen[235]. HSCs may exist as several 
different phenotypes with distinct molecular and cellular 
functions and features, each of which contributes 
significantly to the liver homeostasis and the disease. 
The quiescent stellate cells are critical to the normal 
metabolic functioning of the liver. The liver injury 
provokes the transdifferentiation of quiescent stellate 
cells to their activated phenotype, leading to a metabolic 
reprogramming. That increases the autophagy (to 
fuel the metabolic demands), the amplification of 
parenchymal injury and the development of ‘classic’ 
phenotypic features of activated HSCs/myofibroblasts. 
Through these changes, the activated stellate cells drive 
the fibrotic response to injury and the development of 
cirrhosis. As liver injury subsides, the activated stellate 
cells can be eliminated by one of three pathways: 
Apoptosis, senescence or reversion to an inactivated 
phenotype. The senescent stellate cells are more likely 
to be cleared by the NK cell-mediated cell death while 
the inactivated stellate cells remain ‘primed’ to respond 
to further liver injury. Reduction in the number of 
activated stellate cells contributes to the regression of 
fibrosis or cirrhosis and the liver repair in most, but not 
all patients. The relative inputs of these three pathways 
on the fibrosis regression are not clearly defined[233]. The 
HCV-specific CD8+ T cells expressing PD-1, a marker 
for exhaustion, were found at the time of the acute 
phase[236]. The acquisition of a memory phenotype and 
the recovery of an efficient CD8+ T cell function declined 
with HCV infections PD-1 expression, whereas, when 
HCV persisted and the HCV-specific CD8+ cells remained 
dysfunctional, high levels of PD-1 were maintained, the 
PD-1 ligation likely provides an overall inhibitory signal 
to Tregs cells shown in a study of PD-1 expression on 
Tregs in humans during the chronic HCV infection. In 
response to HCV antigens, the PD-1 blockade enhanced 
an interleukin-2 (IL-2)–dependent proliferation of 
intrahepatic Tregs and enhanced the overall ability 
of Tregs to inhibit T-effector cells. An increase in 
Treg proliferation with PD-1 blockade was linked to 
this effect[237]. A typical model of the wound-healing 
response to a persistent liver injury is the hepatic fibrosis 
occurring in the chronic hepatitis C[238]. Cytokines and 
chemokines capable of activating hepatic stellate cells 
to secrete collagen are secreted by the inflammatory 
cells of the intrahepatic infiltrate[239,240]. Thus, the 
fibrogenesis seems to be linked to the HCV expression 
through indirect mechanisms, mediated by a virally 
driven inflammation, but the direct role of viral factors in 
the disease progression should be investigated in more 
details. The cell injury, such as an oxidative stress and 
a steatosis, may be induced specifically by several viral 
proteins alone which could directly activate the hepatic 
stellate cells[241,242]. These observations may explain why 
some patients with chronic hepatitis C with normal liver 
enzymes and a minimal/mild inflammation may present 
a significant liver fibrosis as shown by the histology of 
liver biopsies. Overall, up to 70% of patients with a HCV 
cirrhosis will demonstrate a reversibility on follow-up 
biopsies[243-248]. Moreover, a reduced portal pressure and 
a decreased all-cause mortality are improved when the 
reversal occurs[245]. It is to point out that approximately 
10% of HCV patients present a persistent or even 
progressive fibrosis following SVR, which might reflect 
other concurrent underlying liver diseases, especially a 
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nonalcoholic fatty liver disease (NAFLD)[248]. The stellate 
cells can respond to cytokines and growth factors after 
priming stimuli. Then the proliferation, contractility, 
fibrogenesis, matrix degradation and proinflammatory 
signaling are enhanced. Now, it is clear that there 
are disease-specific pathways of fibrosis, without all 
activated cytokine pathways[249,250]. This is especially 
relevant to NAFLD, where there are many convergent 
pathogenic routes[248-250]. Importantly, different families 
of inflammatory cell types and their subsets may either 
promote or inhibit fibrosis[249-252].
Alterations of lipid metabolism 
Lipids are required for the HCV replication and particles 
assembly. As mentioned above, HCV can modify the 
host serum lipid profile and this(ese) modification(s) can 
provoke the steatosis[253]. The steatosis is more frequent 
and more severe in patients with HCV gt 3 and it is 
correlated with a high HCV RNA levels. On one hand, in 
HCV-infected patients, the steatosis can be considered 
as a marker of the liver disease progression[254] and, on 
the other hand, as an indication of the reduced response 
to therapy[254]. However, if it is not metabolic or alcoholic 
steatosis, an efficient antiviral therapy is capable to 
reduce it[255,256].
Extrahepatic replication of HCV
The apparent presence of the HCV genomes in extra-
hepatic sites of patients infected with HCV has been 
shown. Using sensitive PCR assays, the HCV was 
revealed in leukocytes and there are evidences that 
these cells may represent a reservoir of the virus after 
treatment[257,258]. Interestingly, the pool of the HCV 
quasi-species differs between the plasma and peripheral 
blood monocytes, suggesting an independent spread 
of HCV within different cell types[259,260]. The infection 
of B-cells from non-Hodgkin’s lymphoma by HCV 
has also been demonstrated. A cell line established 
from transformed lymphocytes supported the HCV 
replication and also enable production of infectious viral 
particles capable to infect peripheral blood B cells[261]. 
The significance of these extrahepatic HCV reservoirs 
is not well understood, although one could speculate 
that the leukocyte compartments might represent an 
additional route by which HCV can directly manipulate 
the immune system and also another means by which 
the virus avoids the eradication.
Extrahepatic manifestations associated with the HCV 
infection
At least, one clinically significant extrahepatic manifes-
tation occurs in 38% to 76% of HCV infected patients 
with chronic HCV[262,263]. The most frequent associated 
pathology is a mixed cryoglobulinemia. It is detected 
in 19% to 50% of HCV infected patients, while only 
15% of them are symptomatic. The cryoglobulins are 
immunoglobulins which precipitate at a temperature 
below 37 ℃. They are produced by HCV activated B cells. 
The cryoglobulins deposed in small and medium vessels 
are the cause of systemic vasculitis which can manifest 
in level joint, skin, renal or peripheral nerves[262]. Other 
observed extrahepatic manifestations are the following: 
lymphoma, thyroid disorders, diabetes, xerostomia and 
xerophthalmia[263-265]. The HCV infection cure leads to 
a gradual decrease of the cryoglobulin level in serum, 
followed by the remission of cryoglobulin-related 
symptoms and pathologic lesions[265]. Interestingly, as 
a result of treatment the incidence of type 2 diabetes is 
also reduced by approximately two thirds[264,265].
CLINICAL MANIFESTATION OF HCV 
INFECTION
Acute hepatitis
The acute hepatitis C is asymptomatic in 90% of infected 
people[266]. In some cases, asthenia, fever and muscle, 
and joint pain can appear. While, signs of jaundice are not 
frequent. Acute hepatitis C is characterized by a transient 
increase in the rate of serum transaminases. The first 
detectable virus marker is viral RNA that appears one 
to two weeks after exposure. Then seven-eight weeks 
later, the anti-HCV IgG response can be detected[266-268]. 
In 20% of cases, hepatitis C is resolved spontaneously 
through the innate and adaptive immunity[269]. The 
viral RNA becomes undetectable within three to four 
months after infection. Various factors could promote 
the viral clearance. Similarly, hepatitis acute symptoms 
would reflect a significant immune response of the 
host. The gene polymorphism of interleukin (IL) 28B 
also influences the host immune response[268,269]. The 
fulminant hepatitis C is exceptional[268].
Chronic infection
In about 80% of cases[268], the immune system is not 
capable to eradicate the HCV during the acute phase of 
infection. When the viral replication persists for more 
than six months after acute infection, the hepatitis is 
considered chronic. At the stage of chronic hepatitis, 
most patients are asymptomatic and may have no 
non-specific symptoms such as fatigue, arthralgia or 
myalgia. The transaminase levels may be moderately 
increased or even normal[270]. The long-term evolution of 
chronic infection is variable. The factors that accelerate 
the disease progression are the following: acquisition 
of more than 40 years, male gender, co-infection by 
HIV, higher body mass index, fatty liver and alcohol 
consumption[269]. After 10 to 30 years, about 20 to 
30% of patients develop a cirrhosis. The cirrhosis may 
be associated with a liver failure, as a decompensation 
following a portal hypertension (ascites, gastrointestinal 
bleeding, etc.). In cirrhotic patients, the risk of death 
from complications is 4% per year, and their risk of 
developing an hepatocellular carcinoma (HCC) is 1 to 5% 
per year. Thirty-three percent of patients with HCC die 
within one year after diagnosis[269,270]. Overall, among 
patients with cirrhosis, the 5-year survival rate is 50%. 
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In fact, the decompensated cirrhosis is the leading 
cause of liver transplantation[268,269] (Figure 8).
DIAGNOSTIC
For HCV diagnosis both serologic and nucleic acid-based 
tests were developed[270,271]. Serologic tests are sufficient 
when chronic hepatitis C is expected, with a sensitivity 
of more than 99% if using the 3rd generation assays. 
Positive serologic results require additional HCV RNA 
or (with slightly reduced sensitivity) HCV core antigen 
measurements in order to differentiate between chronic 
hepatitis C and resolved HCV infection from the past. 
When an acute hepatitis C is considered, a serologic 
screening alone is insufficient, because mature anti-HCV 
antibodies are developed late after transmission of the 
virus. 
Morphological methods like immunohistochemistry, 
in situ hybridization or PCR from liver specimens 
play no relevant role in the diagnosis of hepatitis C 
because of their low sensitivity, poor specificity and low 
efficacy compared to serologic and nucleic acid-based 
approaches.
HCV core antigen assay
Recently, a new quantitative HCV core antigen assay 
(Architect HCV Ag, Abbott Diagnostics) was approved 
by the EMA. This assay comprises 5 different antibodies 
targeted the HCV core. The test is highly specific (99.8%), 
equally effective for different HCV genotypes, and shows 
a relatively high sensitivity for the determination of 
chronic hepatitis C (corresponding to 600-1000 IU/mL 
HCV RNA). However, HCV core antigen correlated well, 
but not fully linearly, with HCV RNA serum levels, and 
false-negative results might be obtained in patients 
with an impaired immunity[271-273]. Another study has 
shown that the HCV core antigen quantification could 
be an alternative to the HCV RNA quantification for on-
treatment antiviral response monitoring[274]. Here, a HCV 
core antigen below the limit of quantification at treatment 
1 wk was strongly predictive of RVR, whereas patients 
with a less than 1 log10 decline in HCV core antigen 
at treatment 12 wk had a high probability of achieving 
nonresponse. The new HCV core antigen assay could be 
a cheaper, though somewhat less sensitive, alternative 
for nucleic acid testing.
Nucleic acid testing for HCV
Since the HCV RNA is detectable within a few days of 
infection; the nucleic acid-based tests are efficient in 
an early diagnostic of acute hepatitis C and should be 
considered as mandatory. The HCV RNA measurement 
is furthermore important in determination of the HCV 
genotype, selection of treatment strategy, therapy 
duration and evaluation of the treatment success[274]. 
For a number of antiviral combination therapies, the 
HCV RNA follow-up studies are essential to define 
the outcome of the treatment and further therapeutic 
strategies, if necessary. Traditionally, the tests should 
be repeated 24 wk after treatment completion to 
assess whether a sustained virologic response (SVR) 
has been achieved. However, as the probability of a 
virologic relapse is similar after 12 and 24 wk, the new 
time point for assessment of final virological treatment 
outcome is 12 wk after the end-of-treatment[275,276]. Both 
qualitative and quantitative PCR-based detection assays 
are available. Qualitative PCR tests are sensitive and are 
used for initial diagnostic of hepatitis C, for screening of 
blood and organ donations and for confirming SVR after 
treatment completion (Table 2). Quantitative reverse 
transcriptase (RT) real-time PCR-based assays can detect 
and quantify the HCV RNA over a very wide range, 
from approximately 10 IU/mL to 10 million IU/mL. The 
measurements are essential in the treatment monitoring 
when the virus load is gradually reducing.
HCV genotyping
HCV genotyping is mandatory for every patient who 
considers antiviral therapy[277]. For DAA-based therapies, 
the determination of HCV genotypes and even subtypes 
is important because of significantly distinct barriers 
to resistance on the HCV subtype level. However, the 
importance for the HCV genotyping may decline with 
the availability of highly and broadly effective all oral 




< 30% > 70
Recovery Chronic infection










A > 1  F > 1
Figure 8  Natural history of hepatitis C virus infection and start to treat. 
The recommendation to treat chronic hepatitis is usually a “significant” fibrosis 
as defined by a Child–Pugh score (A to C) and a fibrosis grade (F) greater 
than 1 by the Metavir scoring system, with usually a significant necrotic-
inflammation as defined by an activity stage greater than 1 by the Metavir 
scoring system[288,289]. The Child–Pugh score employs five clinical measures 
of liver disease: Total bilirubin, Serum albumin, Prothrombin time, Ascites, 
Hepatic encephalopathy. The letter F refers to the scars of the liver caused by 
the aggression. It is classified from F0 to F4: F1, F2 are minimal to moderate 
fibrosis, F3 corresponds to a pre-cirrhotic stage and F4 corresponds to 
cirrhosis. Red arrows indicated the time to start treatment[290].
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analysis and reverse hybridization technology allow the 
HCV genotyping. Initial assays were designed to analyze 
exclusively the 5’UTR, which was burdened with a high 
rate of misclassification especially on the subtype level. 
Current assays were improved by additionally analyzing 
the coding regions, in particular the genes encoding 
core protein and the NS5B, both of which provide non-
overlapping sequence differences between the genotypes 
and subtypes[278,279].
TREATMENT
All people with confirmed chronic HCV infection should 
be offered a high-quality care as soon as possible. 
Simultaneously, the screening and management of 
alcohol use is essential to prevent the progression 
to cirrhosis[278,280]. The modelling suggests that the 
treatment early in the course of HCV disease for all 
or specific populations could prevent the disease 
progression and onward transmission[281-283]. In fact, 
not all people with chronic HCV infection will progress 
to fibrosis[284]. So, medical authorities of a country to 
should decide when to start anti-HCV treatment. It 
should be emphasized that the transmission has been 
documented among people recently cured who lacked 
access to prevention services[285]. More research is 
needed to determine cost-effective eligibility criteria 
for both key and other populations that maximize 
reductions in the HCV-related morbidity, mortality, and 
transmission in different epidemiological contexts. 
The WHO guidelines recommend the prioritizing 
treatment among people with an advanced fibrosis or 
cirrhosis in order to prevent a liver cancer[286]. The HCV 
co-infection in people living with HIV increases mortality 
while HIV has been shown to accelerate the progression 
of HCV disease[287,288]. Therefore, people with HIV/HCV 
co-infection may also warrant treatment prioritization. 
The stage of HCV disease could be estimated through 
liver biopsy (METAVIR system) identifying individuals 
needing an immediate treatment[288]. However, the liver 
biopsy test is expensive and can lead to complications 
such as infections, excessive bleeding, pain, or accidental 
injury to other organs. The use of liver function tests and 
platelet counts to determine the degree of liver fibrosis, 
such as the aminotransferase-to-platelet ratio index and 
the Fibrosis-4 score could be a non-invasive alternative 
and a more useful approach for gauging treatment 
eligibility across different tiers of health systems[289,290]. 
Monitoring systems should be put in place for people 
who do not initiate treatment immediately.
In the course of the last two decades, treatment of 
the HCV infection has significantly improved. For nearly 
15 years, the combination of pegylated interferon alfa 
and ribavirin (PR) allowed a moderate sustain virologic 
response (SVR). Cure of the infection was achieved in 
45% of genotype 1 and 65% of genotype 3 and around 
85% of genotype 2 infected patients[291]. Development 
of the direct-acting antiviral drugs (DAAs) targeting 
viral proteins (NS3/4A protease, NS5B polymerase with 
nucleotide and non-nucleotide inhibitors, NS5A viral 
replication complex) was achieved due to the better 
understanding of the HCV life cycle. It revolutionized 
the treatment of chronic hepatitis C[292,293]. The classes 
of oral anti-HCV inhibitors and their characteristics are 
shown (Table 3). The combination of PR with the first-
generation protease inhibitors demonstrated a high 
antiviral effectiveness (75% of SVR, but restricted to 
genotypes 1) with substantial adverse effects for the 
first-generation protease inhibitors. In 2011, telaprevir 
and boceprevir obtained a market approval. In 2012, the 
recommendations were approved for their use in HCV 
mono- and in 2013 for HCV/HIV co-infected infected 
patients. Then, SVR rates increased from 75% to 90% 
while reducing treatment duration, adverse effects, and 
the number of pills, thanks to the combination of PR 
with second-generation protease inhibitors[63,294,295]. From 
2015 the standard of care is a combination of DAAs. 
Sofosbuvir, daclatasvir and the sofosbuvir/ledipasvir 
combination are part of the preferred regimens in the 
WHO guidelines, and can achieve cure rates above 
95%[63]. These medicines are much more effective, 
safer and better-tolerated than the older therapies. 
In the first studies, excellent results were obtained on 
a group of so-called “easy-to-treat patients” and in 
Table 2  Commercially available hepatitis C virus RNA detection assays
Assay Distributor Technology Detection limits (IU/mL) Genotypes Approval status
Qualitative HCV RNA detection assays
  AmplicorTM HCV 2.0 Roche molecular Systems PCR 50 All FDA, CE
  VersantTM HCV Siemens Medical Solutions Diagnostics TMA 5-10 All FDA, CE
Quantitative HCV RNA detection
  AmplicorTM HCV Monitor 2.0 Roche molecular Systems PCR 500 to approximately 5.105 All CE
  HCV SuperQuantTM National Genetics institute PCR 30 to 107 All U.S only
  VersantR HCV RNA 3.0 Siemens Medical Solutions Diagnostics bDNA 615 to 8.106 All FDA, CE
  CobasR AmpliPrep/High pure
  system/CobasR TaqManR
Roche molecular Systems Real-time PCR 15 to 107 All FDA, CE
Abbot RealTimeTM HCV Abbot Diagnostics Real-time PCR 10 to 107 All FDA, CE
Artus HCV QS-RGQ assay Qiagen Real-time PCR 34 to 108 All CE
VersantRR HCV 1.0 kPCR assay Siemens Real-time PCR 10 to approximately 107 - CE
HCV: hepatitis C virus; TMA: Transcription-mediated amplification of RNA; bDNA: Branched DNA hybridization assay.
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small groups of patients have been confirmed in the 
phase Ⅲ studies and in ”difficult-to-treat patients” 
[such as in check of previous regimens (including 
protease inhibitors), cirrhotic patients, liver or kidney 
transplanted patients, HIV infected patients or multi-
drug treated patients, at an increased risk of the drug 
interaction][63]. Nevertheless, viral variants resistant to 
DAAs can emerge during the antiviral therapy[295-298] 
Table 3  Selected directly acting antiviral agents and host targeting agents in the pipeline[63]
Drugs name Company Target/active site Phase
NS3/4A protease inhibitors
  Vaniprevir (MK-7009) Merck Active site/macrocyclic Ⅲ
  Voxilaprevir GS-9857 Gilead Active site Ⅲ
  Glecaprevir (ABT-493) Abbvie Active site Ⅲ
  IDX21437 Idenix Active site Ⅱ
  Sovaprevir (ACH-1625) Achillion Active site/macrocyclic? Ⅱ
Nucleoside analog NS5B polymerase inhibitors (NI)
  MK-3682 (formerly IDX20963) Merck Active site Ⅱ
  ACH-3422 Achillion/Janssen Active site Ⅱ
Non- Nucleoside analog NS5B polymerase inhibitors (NNI) 
  Beclabuvir (BMS-791325) Bristol-Myers Squib NNI site 1/Thumb 1 Ⅲ
  Setrobuvir (ANA598) Anadys/Roche NNI site 4?/palm 1 Ⅱ
NS5A inhibitors
  BMS-824393 Bristol-Myers Squibb NS5A protein Ⅱ
  PPI-461 Presidio NS5A protein Ⅱ
  PPI-668 Presidio NS5A protein Ⅱ
  Pibrentasvir (ABT-530) Abbvie NS5A protein Ⅲ
  ACH-2928 Achillion NS5A protein Ⅰ
  Ruzasvir (MK-8408) Merck NS5A protein Ⅱ
Host targeting agents
  SCY-635 Scynexis Cyclophilin inhibitor Ⅱ
  Miravirsen Santaris miRNA122 antisense NA Ⅱ
  RG-101- Regulus miRNA122 antisense NA Ⅱ
  TT-0034 Tacere Therapeutics RNA interference with HCV Ⅱ
Table 4  Selected directly acting antiviral agents and host targeting agents whose development has been stopped or temporarily halted[63]
Drugs name Company Target/Active site
NS3 /4A protease inhibitors
  Ciluprevir BILN 2061 Boehringer Ingelheim Active site/macrocyclic
  Narlaprevir (SCH900518) Schering-Plough Active site/linear
  PHX1766 Pheromix Active site
  Danoprevir (R7227) Roche/InterMune Active site/macrocyclic
  Faldaprevir (BI201335) Boehringer Ingelheim Active site/linear
  Telaprevir (VX-950) Vertex Withdrawn
  Boceprevir (SCH503034) Merck Withdrawn
Nucleoside analogue NS5B polymerase inhibitors (NI)
  Valopicitabine (NM283) Idenix/Novartis Active site
  R1626 Roche Active site
  Mericitabine (R7128) Roche/Pharmasset Active site
  GS-938 Gilead Active site
  IDX184 Idenix Active site
Non-nucleoside NS5B polymerase inhibitors (NNI)
  BILB 1941 Boehringer Ingelheim NNI site 1/thumb
  MK-3281 Merck NNI site 1/thumb 1
  VX-759 Vertex NNI site 2/thumb 2
  VX-222 Vertex NNI site 2/thumb 2
  VX-916 Vertex NNI site 2/thumb 2
  ABT-072 AbbVie NNI site 3/palm 1
  HCV-796 ViroPharma/Wyeth NNI site 4/palm 2
  Filibuvir (PF-00868554) Pfizer NNI site 2/thumb 2
  IDX375 Idenix NNI site 4/palm 2
  Tegobuvir (GS-9190) Gilead NNI site 4/palm 2
  GS-9669 Gilead NNI site 3/palm 1
  Deleobuvir Böhringer NNI site 3/palm 1
Host targeting agents
  NIM811 Novartis Cyclophilin inhibitor
  Alisporivir (Debio-025) Novartis Cyclophilin inhibitor
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(Table 4). The estimation of a putative virus resistance 
profile prior to an antiviral therapy can help to select the 
optimal treatment regimen for individual patients[295,296].
CONCLUSION
A prominent genetic diversity of HCV in combination 
with non-trivial replication cycle poses serious problems in 
virus research and therapy of virus-associated diseases. 
However, during the last several years a significant 
progress in understanding of the HCV molecular biology 
and pathogenesis has been achieved. In many aspects 
that allows to making a great step forward towards 
antivirals design, that result in DAA therapy. However, 
even with the new drugs the HCV-associated problems, 
of both fundamental and applied origin, are not solved. 
In fact, the resolution of these problems is going hand 
in hand. 
First, in the absence of direct cytopathic effect, the 
mechanism of lipid deregulation, that results in liver 
pathologies, is not completely understood. Second, 
the system of the HCV control during latency and 
putative triggers of virus active replication were poorly 
investigated. Third, design of prophylactic vaccine 
is still in its infancy. Finally, the access to drugs and 
therapies for the people leaving in the third world is 
very restricted. Even if SVR rates > 90% are reached, 
nearly 10 million people will be living without treatment 
options[63]. Indeed, an easy access to diagnosis and 
treatment is still missing to drug users, people in 
difficult socio-economic situations, migrants, prisoners, 
because of themselves or health policy. 
Therefore, fundamental studies on virus-cell inter-
actions and studies directing towards development of 
the prophylactic vaccine should be intensified. 
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